Takeover of Biotest AG by Chinese strategic investor Creat Group
Clients OGEL GmbH
Jones Day advised OGEL GmbH as holder of 50.61 percent of the Ordinary Shares in Biotest AG, Germany, in connection with the acquisition of Biotest by way of a public takeover offer made by a company controlled by CREAT Group, China. The enterprise value of Biotest is €1.203 billion. Biotest is a global company that supplies plasma protein products and biotherapeutic drugs.